Why the study?
Do nitric oxide synthase (NOS) inhibitors improve hemodynamics in patients and animal models with septic shock?
Do nitric oxide synthase (NOS) inhibitors improve hemodynamics in patients and animal models with septic shock?
NOS inhibitors show marked antihypotensive activity and low toxicity in human septic shock, highlighting the limitations of certain animal models in predicting clinical responses.
Answers are grounded in this paper and cite their sources.
May support NOS inhibitor evaluation in human septic shock; leaves open translation from animal models and requires prospective trials.
Septic shock is a physiological derangement of the cardiovascular system characterized by pathological vasodilation. Recent studies have established a role for nitric oxide, previously known as endothelium-derived relaxing factor, in the vascular dysfunction of sepsis. This finding suggests that inhibition of nitric oxide synthase (NOS), the enzyme responsible for nitric oxide production, could be a target for therapeutic intervention. Animal studies have provided conflicting results, demonstrating both beneficial and detrimental effects. We provide here an overview of the preclinical studies of NOS inhibitors and an update of the clinical studies. The low toxicity and marked antihypotensive activity of NOS inhibitors in humans highlight some of the drawbacks of certain animal models and provide important insights into the experimental study of septic shock.
No takes yet. Share an insight, caveat, or question.
Kilbourn et al. (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: